戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ents undergoing evaluation for renal mass or urinary stone.
2  would increase the options for treatment of urinary stones.
3 ubject focuses on pathogenesis of infectious urinary stones.
4 ter encrustation, blockage, and formation of urinary stones.
5 at results in the formation of cystine-based urinary stones.
6 al deposition consistent with development of urinary stones.
7 rial communities but not luminal clusters or urinary stones.
8 s of patients suffering from infections with urinary stones and infectious stones.
9 nvestigate nephrourological diseases such as urinary stones and renal masses.
10 ent, dribbling urination, bladder infection, urinary stones, and widely dilated ocular pupils that do
11 ropathogenProteus mirabilisfrequently causes urinary stones, but little has been known about the init
12  enzyme which can increase urine pH and form urinary stones, causing catheter blockage and facilitati
13 rmance of VUE images remained suboptimal for urinary stone detection due to subtraction of stones 3 m
14                    Diagnostic performance in urinary stone detection was summarized by using area und
15 etic diagnosis was highest for patients with urinary stone disease (three out of three individuals),
16                                              Urinary stone disease (USD) is a major health burden aff
17                            The prevalence of urinary stone disease (USD) is rapidly rising.
18  a cluster of chronic diseases that includes urinary stone disease (USD), obesity, diabetes, cardiova
19 t international consortium for microbiome in urinary stone disease - MICROCOSM - was created and cons
20     Patients with neurological disorders and urinary stone disease pose a significant challenge to th
21 loped a pre-eminent role in the diagnosis of urinary stone disease, it has also found favour as a val
22 various conditions, such as kidney disorder, urinary stone disease, urinary tract infection, and cyst
23 lockers or alpha blockers were used to treat urinary stone disease.
24 ormation and establish a new mouse model for urinary stone disease.
25                                    Among 166 urinary stones evaluated, diagnostic performance of VUE
26 orithm in patients undergoing renal mass and urinary stone evaluation.
27 sis of urea to CO(2) and NH(3), resulting in urinary stone formation in individuals with complicated
28 on as a novel approach for the prevention of urinary stone formation.
29 etabolic syndromes, cardiovascular diseases, urinary stone, obesity, type 2 diabetes.
30                 Kidney stones (also known as urinary stones or nephrolithiasis) are highly prevalent,
31 t pharmacologic means of increasing rates of urinary stone passage.
32 cal therapy is an option for facilitation of urinary-stone passage for patients amenable to conservat
33                    Medical therapies to ease urinary-stone passage have been reported, but are not ge
34 in lithotripsy, the presence of infection in urinary stone patients as well as infectious stones are
35            This review examines a variety of urinary stone presentations and treatment strategies for
36                          Although changes in urinary stone risk factors may reduce the need for surgi
37                                  Seventy-one urinary stones (size: 2.7-14.1 mm) of known chemical com
38               Consequently, patients develop urinary stones that are principally composed of indinavi
39 hold-based CT method can be used to quantify urinary stone volume even at low radiation doses.
40          This result sets PC apart from most urinary stones, which largely are composed of calcium ox
41 hase dual-energy CT enabled the detection of urinary stones with moderate accuracy.